Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma

Hematol Oncol Clin North Am. 2016 Dec;30(6):1261-1275. doi: 10.1016/j.hoc.2016.07.011.


Primary mediastinal B-cell lymphoma is characterized by a high chance of cure, and cured patients have a long disease-free life-expectancy; however, prognosis is severe in the case of relapsed or refractory disease. The initial use of the most effective chemoimmunotherapy regimen is therefore crucial. Understanding who will benefit from postinduction radiotherapy is also of paramount importance; positron emission tomography may be a reliable guide for physicians in determining which patients will require consolidation. New drugs with mechanisms of action including the most relevant biologic features of the tumor may allow better disease control.

Keywords: Anti-PD-1; Brentuximab vedotin; Fluorodeoxyglucose positron emission tomography; Methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin, prednisone; Primary mediastinal B-cell lymphoma; Radiotherapy; Rituximab; Ruxolitinib.

Publication types

  • Review

MeSH terms

  • Consolidation Chemotherapy / methods*
  • Disease-Free Survival
  • Humans
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / mortality
  • Mediastinal Neoplasms / diagnosis*
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / mortality
  • Survival Rate